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Midterm Follow-up after Cryopreserved Homograft Replacement in 
the Aortic Position
Samina  Park,  M.D.,  Ho  Young  Hwang,  M.D.,  Ph.D.,  Kyung-Hwan  Kim,  M.D.,  Ph.D., 
Ki-Bong  Kim,  M.D.,  Ph.D.,  Hyuk  Ahn,  M.D.,  Ph.D.
Background:  The long-term results of homografts used in systemic circulation are controversial. We assessed the 
long-term results of using a cryopreserved homograft for an aortic root or aorta and its branch replacement. 
Materials and Methods: From June 1995 to January 2010, 23 patients (male:female=15:8, 45.4±15.6 years) under-
went a homograft replacement in the aortic position. The surgical techniques used were aortic root replacement in 
15 patients and aortic graft interposition in 8 patients. Indications for the use of a homograft were systemic vascu-
litis (n=15) and complicated infection (n=8). The duration of clinical follow-up was 65±58 months. Results: Early 
mortality occurred in 2 patients (8.7%). Perioperative complications included atrial arrhythmia (n=3), acute renal fail-
ure (n=3), and low cardiac output syndrome (n=2). Late mortality occurred in 6 patients (26.1%). The overall sur-
vival rates at 5 and 10 years were 66.3% and 59.6%, respectively. Six patients (28.6%) suffered from homo-
graft-related complications. Conclusion: Early results of homograft replacement in aortic position were favorable. 
However, close long-term follow-up is required due to the high rate of homograft-related events.
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INTRODUCTION
The  cryopreserved  homograft  has  been  used  as  an  alter-
native to the artificial vascular graft or composite valved con-
duit [1-3]. Its advantages include excellent hemodynamics, no 
need  for  anticoagulation,  and  resistance  to  infection  [4-8]. 
However,  its  use  has  been  limited  due  to  the  lack  of  avail-
ability of donors and concern about long-term durability [5,9]. 
The aims of this study were to evaluate the long-term results 
of  surgery  performed  with  a  cryopreserved  homograft  in  the 
aortic  position  including  the  a o r t i c  r o o t  o r  a o r t a  a n d  i t s  
branch, and to compare those according to the indications and 
surgical  techniques  used.
MATERIALS AND METHODS
1) Patient characteristics
From  June  1995  to  January  2010,  23  patients  underwent 
homograft  replacement  in  the  aortic  position.  Fifteen  of  the 
patients  were  male,  and 8  were  female.  The  mean  age at  the Homograft in Aortic Position
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Table 1. Preoperative characteristics of study patients
Variables Values
Age  (yr)
Female 
NYHA  class≥III
Smoking 
Hypertension 
Diabetes  mellitus
Overweight  (BMI≥25)
Dyslipidemia
CVA  history
Chronic  renal  failure 
Diagnosis
Behçet  disease
Takayasu  arteritis
Infective  endocarditis
Infectious  aortitis/vasculitis
45.4±15.6
  8  (34.8)
  7  (30.4)
  5  (21.7)
  6  (26.1)
  4  (17.4)
  4  (17.4)
2  (8.7)
1  (4.3)
1  (4.3)
14  (60.9)
1  (4.3)
  3  (13.0)
  5  (21.7)
Values  are  presented  as  mean±standard  deviation  or  number  (%).
NYHA=New  York  Heart  Association;  BMI=body  mass  index 
(kg/m
2);  CVA=cerebrovascular  accident.
time  of  surgery  was  45.4±15.6  years.  Hypertension  (n=6, 
26.1%) and diabetes mellitus (n=4, 17.4%) were common co-
morbidities  (Table  1).  Indications  for  the  use  of  a  homograft 
were  1)  systemic  vasculiti s  ( n = 1 5 )  s u c h  a s  B e h çet  disease 
(n=14)  and  Takayasu  arteritis  (n=1)  and  2)  complicated  in-
fection  (n=8)  involving  the  aortic  root  (n=3)  or  aorta  and  its 
branch  (n=5).  The  surgical  techniques  used  were  aortic  root 
replacement  in  15  patients  and  aortic  graft  interposition  in  8 
patients.
2) Surgical procedures
The  basic  surgical  procedures  of  aortic  root  replacement 
(ARR)  have  been  previously  described  [10].  ARR  was  per-
formed  under  standard  aortic  and  bicaval  cannulation  via  a 
median  sternotomy.  In  addition  to  moderate  systemic  hypo-
thermia,  direct  antegrade  cardioplegia  and/or  retrograde  car-
dioplegia  through  the  coronary  sinus  were  administered.  Any 
root  defects  induced  by  vasculitis  or  infection  were  obli-
terated with a commercially available bovine pericardial patch 
or  mitral  anterior  leaflet  tissue  of  the  homograft.  All  anasto-
moses  were  performed  with  non-absorbable  monofilament 
sutures. Proximal anastomosis  was performed  using  4-0  inter-
rupted polypropylene sutures and tied after reinforcing the su-
tu re line w ith a b ovine p ericar di al strip. Both coronary artery 
buttons  were  attached  to  the  new  coronary  aortic  sinuses  us-
ing  5-0  polypropylene  continuous  sutures.  No  other  materials 
besides  bovine  pericardium  and  monofilament  suture  were 
used  to  minimize  the  risk  of  infectious  complications.  The 
mean  cardiopulmonary  bypass  time  and  aortic  cross  clamp 
time  were  300±116  minutes  and  192±85  minutes,  respec-
tively.  Replacement  of  aorta  and  its  branch  was  performed 
via  a  thoracoabdominal  incision  (n=4),  or  median  sternotomy 
w i t h  o r  w i t h o u t  a n  o b l i q u e  n e c k  i n c i s i o n  ( n = 4 ) .  A l l  s u t u r e s  
were placed with polypropylene alone to minimize the risk of 
infection.  The  size  of  the  homograft  was  marked  as  an  inner 
diameter  of  the  aortic  valve  level  and  the  mean  size  of  the 
homograft  was  24.2±2.4  mm.
3) Evaluation of clinical outcomes
The  patients  underwent  regular  postoperative  follow-up 
through  the  outpatient  clinic  at  3  or  4  month  intervals,  and 
they  were  contacted  by  telephone  for  confirmation  of  their 
condition  if  the  last  clinic  visit  was  not  conducted  at  the 
scheduled  time.  Clinical  follow-up  was  closed  on  September 
30,  2010.  Follow-up  was  completed  in  all  patients  with  a 
mean  follow-up  duration  of  66±59  months  (range,  4  to  183 
months).  Cardiac  death  was  defined  as  any  death  related  to 
cardiac events, including sudden death during follow-up. Late 
homograft-related  events  were  defined  as  a  composite  of  car-
diac  death,  infection  of  homograft,  thromboembolism,  homo-
graft-related reoperation or intervention, homograft valve dete-
rioration  causing  valve  regurgitation,  and  anastomosis  site 
pseudoaneurysm.
4) Statistical analysis
Statistical analysis was performed using the SPSS ver. 12.0 
(SPSS  Inc.,  Chicago,  IL,  USA).  Data  were  expressed  as 
mean±standard  deviation  or  proportions.  Comparison  between 
the  2  groups  was  performed  using  the  Fisher’s  exact  test  for 
categorical variables and Student’s t test for continuous varia-
bles.  Survival  rates  were  estimated  using  the  Kaplan-Meier 
m e t h o d  a n d  c o m p a r i s o n s  b e t w e e n  t h e  2  g r o u p s  w e r e  p e r -
f o r m e d  u s i n g  t h e  l o g - r a n k  t e s t .  A  p - v a l u e  o f  l e s s  t h a n  0 . 0 5  
was  considered  statistically  significant.Samina Park, et al
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Table 2. Early clinical results
Variables No.  (%)
In-hospital  mortality 
Postoperative  complications
Uncontrolled  septicemia 
Acute  renal  failure 
Stroke/delirium
Low  cardiac  output  syndrome
Long-term  ventilation
2  (8.7)
-
2  (8.7)
 3  ( 1 3 . 0 )
 3  ( 1 3 . 0 )
2  (8.7)
1  (4.3)
Fig. 1. Log-rank tests demonstrated that overall survival rates were not related to the indication of the use of homograft (A) or the type 
of operation (B). ARR=aortic root replacement.
RESULTS
1) Early clinical outcomes
There  were  2  early  mortalities  (8.7%)  and  both  underwent 
thoracic  aorta  replacement  due  to  a  mycotic  aneurysm  and 
died  of  uncontrolled  sepsis.  Perioperative  complications  in-
cluded  uncontrolled  sepsis  (n=2),  acute  renal  failure  (n=3), 
and  low  cardiac  output  syndrome  (n=2)  (Table  2).
2) Long-term survival
Among the early survivors, late mortality occurred in 6 pa-
tients  (26.1%)  and  all  were  cardiac  deaths.  The  overall  sur-
vival  rates  at  5  and  10  years  were  66.3%  and  59.6%, 
respectively.  Survival  rate  was  not  affected  by  the  causative 
disease  (systemic  vasculitis  versus  infection  involving  the 
a o r t i c  r o o t  o r  a o r t a  a n d  i t s  b r a n c h ,  p = 0 . 8 1 5 )  o r  t h e  s u r g i c a l  
method  (ARR  vs.  aortic  graft  replacement,  p=0.702)  (Fig.  1).
3) Freedom from homograft-related events
Eight  patients  suffered  from  homograft-related  events  as 
f o l l o w s :  h o m o g r a f t  v a l v e  d e t e r i o ration  in  one  patient,  anasto-
mosis  site  pseudoaneurysm  in  five  patients,  and  infective  en-
docarditis in two patients (Table 3). The most common event 
was  anastomosis  site  pseudoaneurysm  (n=5).  Two  of  these  8 
patients  underwent  reoperation  and  another  one  of  the  8  pa-
tients  underwent  a  stent  graft  insertion.  Still  another  one  of 
the  8  patients  underwent  reoperation  and  died  of  sudden  car-
diac arrest on postoperative day 9. The 5- and 10-year homo-
graft related event-free survival rates were 63.1% and 55.2%, 
respectively.  Event-free  survival  was  lower  in  patients  with 
systemic vasculitis than in patients with an infectious disease, 
although the difference was not statistically significant (43.2% 
vs.  83.3%  at  10  years,  p=0.132)  (Fig.  2).  Event-free  survival 
was  not  related  to  the  surgical  method  (p=0.295).
DISCUSSION
The  present  study  demonstrated  two  main  findings  about 
cryopreserved  homograft  replacement  in  the  aortic  position 
with  acute  and  chronic  inflammation.  First,  the  early  results 
of  a  cryopreserved  homograft  used  in  the  aortic  position  in-
cluding  the  aortic  root  or  aorta  and  its  branch  were  accept-
able  with  an  early  mortality  rate  of  8.7%.  Second,  homo-Homograft in Aortic Position
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Table 3. Clinical data of patients who experienced homograft-related complications
Sex/age  (yr) Diagnosis Operation Complication Interval  (mo)
Male/40
Male/51
Male/30
Female/45
Male/50
Male/41
Female/48
Male/53
AR  due  to  Behcet  disease
Infective  endocarditis
AR  due  to  Behcet  disease
AR  due  to  Behcet  disease
AR  due  to  Behcet  disease
AR  due  to  Behcet  disease
Takayasu  arteritis,  DTA  pseudoaneurysm
AR  due  to  Behcet  disease
ARR
ARR
ARR
ARR
ARR
ARR
DTA  replacement
ARR
SVD  (severe  AR)
Infective  endocarditis
Anastomosis  site  pseudoaneurysm
Infective  endocarditis
Anastomosis  site  pseudoaneurysm
Anastomosis  site  pseudoaneurysm
Anastomosis  site  pseudoaneurysm
Anastomosis  site  pseudoaneurysm
152
 1 8
150
111
 1 4
  4
 2 4
 1 5
AR=aortic  regurgitation;  ARR=aortic  root  replacement;  SVD=structural  valve  deterioration;  DTA=descending  thoracic  aorta.
Fig. 2. The difference in homograft-related event-free survival 
rates according to the indications of homograft replacement.
graft-related  events  occurred  more  frequently  in  patients  who 
underwent  homograft  replacement  due  to  systemic  vasculitis, 
although  long-term  survival  was  similar  regardless  of  the  in-
dications  or  types  of  operation.
The  cryopreserved  homograft  has  been  used  as  an  alter-
native to the artificial vascular graft or composite valved con-
duit  [1-3].  Its  advantages  include  excellent  hemodynamics, 
avoidance of anticoagulation, and suitability even in the pres-
ence of infection [4-8]. For these  reasons, the  homograft was 
used  in  patients  with  systemic  vasculitis,  complicated  aortic 
root  endocarditis,  or  mycotic  aneurysm  [2,8,10-12].  However, 
long-term  structural  deterioration  was  one  of  the  main  con-
cerns after the placement of the homografts [5,9,12]. Previous 
studies  have  demonstrated  that  early  results  of  homograft  re-
placement in the aortic position were favorable, despite of the 
fact  that  it  was  usually  performed  in  high  risk  patients  with 
complicated  infections  [8,11,12].  In  the  present  study,  early 
mortality  occurred  in  2  patients  and  both  died  of  uncontrol-
lable  infection  that  continued  from  the  preoperative  period. 
There  were  no  postoperative  homograft-related  complications 
such  as  anastomosis  site  bleeding,  early  dehiscence  of  graft, 
or  graft  infection.
The  overall  survival  rates  at  postoperative  5  and  10  years 
were  66.3%  and  59.6%,  respectively,  with  no  difference  in 
the  type  or  indication  of  homograft  replacement.  Previous 
studies [9,13] have demonstrated that freedom from structural 
valve  deterioration  of  homografts  has  ranged  from  62%  to 
80% at 10 years. In the present study, during follow-up up to 
183  months,  structural  valve  deterioration  was  found  in  only 
one  patient,  13  years  after  the  initial  operation.  However, 
anastomosis site pseudoaneurysm was found in 5 patients and 
infective  endocarditis  occurred  i n  2  p a t i e n t s .  O v e r a l l ,  t h e  
10-year homograft-related event free survival rate was 55.2%.
Systemic  vasculitis  involving  the  aortic  root  and  aorta  is  a 
devastating  clinical  situation.  Conventional  bioprosthesis,  me-
chanical valve, or valved conduit replacement resulted in poor 
early  and  long  term  outcomes  [2,10].  In  the  present  study, 
65%  of  the  study  patients  underwent  homograft  replacement 
due  to  systemic  vasculitis.  We  reported  an  early  favorable 
outcome  without  mortality  in  such  patients  in  a  previous  re-
port  [10].  Anastomosis  site  pseudoaneurysm  is  initiated  by  a 
small  disruption  of  the  anastomosis  site  that  allows  blood  to 
leak  into  the  surrounding  space.  Pseudoaneurysms  have  the 
general  tendency  to  grow  irrespective  of  their  location,  and 
this  could  end  in  rupture  [14].  In  general,  it  seldom  occurs Samina Park, et al
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after homograft replacement [15]. On the contrary, in patients 
with systemic vasculitis, the delayed complication could occur 
after a homograft replacement [2,10]. This might be related to 
poor  tissue  healing  in  the  anastomosis  site  due  to  in-
flammation  in  the  native  aorta  and  long-term  use  of  steroids. 
Our surgical strategy was to avoid the use of artificial materi-
als  such  as  pledget  or  spaghetti  to  minimize  the  risk  of  in-
fectious  and  inflammatory  complications.  This  might  have 
caused  the  high  occurrence  rate  of  anastomosis  site  pseudoa-
neurysm  in  our  study  patients.  Due  to  this  complication,  the 
event-free  survival  rate  was  lower  in  patients  with  systemic 
vasculitis,  although  it  was  not  statistically  significant.
There  are  limitations  to  the  present  study  that  must  be 
recognized.  First,  we  did  not  perform  a  multivariate  analysis 
to  find  risk  factors  for  mortality  or  long-term  complications 
because  finding  any  significant  risk  factor  was  difficult  in 
such  a  small  patient  population.  Second,  the  number  of  en-
rolled  patients  was  relatively  small  for  drawing  a  definite 
conclusion.
CONCLUSION
Early  results  of  homograft  replacement  in  the  aortic  posi-
tion  were  favorable  in  patients  with  systemic  vasculitis  or 
complicated  aortic  infection.  However,  close  long-term  fol-
low-up  might  be  necessary  due  to  a  high  rate  of  homo-
graft-related  events,  especially  when  homografts  are  used  in 
patients  with  systemic  vasculitis.
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